UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 396

Sortiert nach

MDM2 inhibition: an important step forward in cancer therapy

Leukemia, 2020-11, Vol.34 (11), p.2858-2874

2020

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Precision medicine for acute myeloid leukemia

Frontiers in oncology, 2023-07, Vol.13, p.1233757-1233757

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data

BMC bioinformatics, 2016-11, Vol.17 (Suppl 12), p.341-341, Article 341

2016

Link zum Volltext

Verfügbarkeit prüfen

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Haematologica (Roma), 2021-06, Vol.106 (6), p.1559

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Annals of hematology, 2021-05, Vol.100 (5), p.1181-1194

2021

Link zum Volltext

Verfügbarkeit prüfen

Acute Myeloid Leukemia Mutations: Therapeutic Implications

International journal of molecular sciences, 2019-06, Vol.20 (11), p.2721

2019

Link zum Volltext

Verfügbarkeit prüfen

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

Future oncology (London, England), 2020-05, Vol.16 (13), p.807-815

2020

Link zum Volltext

Verfügbarkeit prüfen

IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5202-5207

2009

Link zum Volltext

Verfügbarkeit prüfen

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations

Leukemia, 2021-10, Vol.35 (10), p.2813-2826

2021

Link zum Volltext

Verfügbarkeit prüfen

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission

Cancers, 2024-06, Vol.16 (11), p.2108

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Frontiers in oncology, 2022-01, Vol.11, p.804714-804714

2022

Link zum Volltext

Verfügbarkeit prüfen

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

BMC cancer, 2018-11, Vol.18 (1), p.1117-1117, Article 1117

2018

Link zum Volltext

Verfügbarkeit prüfen

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.2-2, Article 2

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management

Mediterranean journal of hematology and infectious diseases, 2022-11, Vol.14 (1), p.e2022073-e2022073

2022

Link zum Volltext

Verfügbarkeit prüfen

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway

Blood cancer journal (New York), 2021-01, Vol.11 (1), p.7-5, Article 7

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 396

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(375)
Mit Volltextzugriff
(383)

Publikationsform

Artikel
(387)
Berichte
(9)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(125)
Life Sciences & Biomedicine
(123)
Humans
(86)
Hematology
(85)
Oncology
(68)
Male
(54)
Leukemia
(53)
Adult
(49)
Aged
(48)
Female
(47)
Middle Aged
(45)
Acute Lymphoblastic Leukemia
(34)
Acute Myeloid Leukemia
(33)
Mutation
(31)
Patients
(26)
Adolescent
(23)
Chemotherapy
(23)
Prognosis
(21)
Young Adult
(21)
Precursor Cell Lymphoblastic Leukemia-Lymphoma - Genetics
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(139)
Cancer Research
(56)
Clinical Lymphoma, Myeloma And Leukemia
(22)
Journal Of Clinical Oncology
(22)
Hemasphere
(14)
Leukemia
(10)
American Journal Of Hematology
(9)
Haematologica
(9)
British Journal Of Haematology
(7)
Leukemia Research
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

MDM2 inhibition: an important step forward in cancer therapy

Editorial: Precision medicine for acute myeloid leukemia

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Acute Myeloid Leukemia Mutations: Therapeutic Implications

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease

BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway

Suchergebnisse filtern